anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a medicinal composition exhibiting excellent synergistic effects and useful for cardiovascular disorders, peripheral vascular diseases, etc., by simultaneously using an L-carnitine compound useful as a medicine for treating the cardiovascular diseases, etc., and a specific compound extracted from grapes. SOLUTION: This medicinal composition contains the combination of L- carnitine, an alkanoyl L-carnitine (the alkanoyl group is a 2-8C alkanoyl group, especially a 2-6C alkanoyl group) or their pharmacologically acceptable salt with a trihydroxy or tetrahydroxystilbene. The medicinal composition is useful for preventing and treating diabetic peripheral neuropathy in addition to the above-described diseases. Resveratrol, it derivatives and resveratrolcontaining natural materials are especially preferable among the trihydroxy and tetrahydroxy stilbene compounds. The alkanoyl L-carnitine is preferably acetyl, propionyl, butyryl, valeryl or isovaleryl L-carnitine, etc. The mixing ratio of the resveratrol compound with the L-carnitine compound is 1:1-1:1000, especially 1:500 (weight ratio).
BACKGROUND: The landscape of systemic therapies for metastatic hormone-sensitive (mHSPC) and castration resistant prostate cancer (mCRPC) extensively improved within the last decades resulting in a significantly prolonged overall survival. However, subgroup analyses of phase III trials suggest potentially different overall survival outcomes for older adults.
METHODS: We relied on our institutional metastatic prostate cancer database to identify mHSPC and subsequently mCRPC patients. Older adults were stratified according to age groups 70-74 versus ≥75-79 versus ≥80 years at metastatic occurrence. Subsequently, uni- and multivariable time to mCRPC and overall survival analyses were performed.
RESULTS: Of 494 older adults, 217 (44%) were 70-74 versus 180 (36%) 75-79 versus 97 (20%) ≥80 years old. Rates of local prostate cancer treatment differed significantly between all three groups (p < 0.01). Regarding mHSPC treatment, androgen receptor signaling inhibitors (ARSI) were administered in 30-39% of patients and docetaxel with 9% in age group 70-74 years and 6% and 3% in age groups 75-79 years and ≥80 years. Regarding mCRPC treatment, significant differences between treatment proportions were observed (p < 0.01). Most common treatment was ARSI for all three groups. Conversely, chemotherapy was more frequently administered in patients aged 70-74 (16%), relative to 4% and 3% in 75-79 year and ≥80 year aged patients. In univariable and multivariable time to mCRPC analyses, overall survival in mHSPC and OS in mCRPC analyses, no significant differences between all three age groups were observed (all p ≥ 0.3).
CONCLUSIONS: Treatment patterns differ significantly between older adults with metastatic prostate cancer. However, these differences may not result in differences of overall life expectancy.
PURPOSE:To obtain a hair-shampoo composition having improved feeling in shampooing and giving shampooed hair having good feeling by compounding gallic acid or its derivative to a shampoo base containing a surfactant and a cationic polymer compound. CONSTITUTION:The objective composition can be produced by compounding (A) a base containing 5-30 wt.% of a surfactant as an active detergent component and 0.01-5 wt.% of a cationic polymer compound as a conditioning agent component with (B) 0.01-2 wt.% of gallic acid or its derivative and (C) proper amounts of thickener, ultraviolet-absorber preservative, emulsifier, disinfectant, antioxidant, tonic agent, colorant and perfumery. Gallic acid is a benzoic acid derivative having three hydroxyl groups and produced usually by hydrolyzing tannic acid. The gallic acid derivative is e.g. propyl gallate. The heavy feeling is shampooing and deficient refreshing feeling after shampooing can completely be eliminated by the use of the present composition.
PURPOSE:To execute positive B1F sepn. within an analyzing element and to obtain the analyzing element which decreases background and noise and has good sensitivity, accuracy and reproducibility by forming the analyzing element into a laminar body consisting of a reactive layer and absorptive layer. CONSTITUTION:The analyzing element is constituted of the porous reactive layer 1 and the light reflective absorptive layer 2. A specified amt. of a fluid sample is weighed and is mixed with a specified amt. of a labeling material then the mixture is dropped onto the layer 1 of the analyzing element having the above-mentioned constitution. Then the specific component and labeling material in the fluid sample competitively react with the 'material which can specifically conjugate with the specific component' immobilized in the layer 1 and part of the labeling material is immobilized in the layer 1. The labeling material which does not participate in the reaction is immobilized in the layer 2 by conjugating with the labeling absorptive material immobilized in the layer 2. The intensity of the signal occuring from the labeling of the labeling material immobilized in the layer 1 is measured in this stage.
Receives usual care plus Support 1 (MS Nurse Support) which includes one one-to-one, face-to-face session with an MS Nurse Specialist in a hospital setting (or via Skype). The session will include answering newly diagnosed patients' questions about MS, providing psychoeducation and teaching Acceptance and Commitment strategies (Hayes, Strosahl \& Wilson, 1999), and referring to other services (based on needs). Participants will also be given a self-help workbook ('Better living with a diagnosis of MS: Patient Workbook') by the nurses. This session will take place within 2 weeks of diagnosis and last up to 90 minutes. It will be supplemented by phone calls (depending on participant needs). MS Nurses will receive training and on-going supervision from experienced clinical psychologists.
Phase I dose level 1 participants received nivolumab 1 mg/kg and ipilimumab 3 mg/kg intravenously (IV) on day 1 of each 21-day cycle and the original starting troriluzole dose of 140 mg orally in the morning as well as 280 mg orally in the evening every day of each 21-day cycle. Participants were treated until disease progression or unacceptable toxicity.
POSFREA Injection contains palonosetron as palonosetron HCl, an antiemetic and antinauseant agent. It is a serotonin-3 (5-HT3) receptor antagonist with a strong binding affinity for this receptor. Chemically, palonosetron HCl is: (3aS)-2-[(S)-1-Azabicyclo [2.2.2]oct 3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1Hbenz[de]isoquinoline hydrochloride. The empirical formula is C19H24N2O.HCl, with a molecular weight of 332.87. Palonosetron HCl exists as a single isomer and has the following structural formula:

Palonosetron HCl is a white to off-white crystalline powder. It is freely soluble in water and soluble in propylene glycol and slightly soluble in ethanol and 2-propanol.

POSFREA Injection is a sterile, clear, colorless, non-pyrogenic, isotonic, buffered solution for intravenous administration. POSFREA Injection is available as 5 mL single- dose vial or 1.5 mL single dose vial.

Each mL of aqueous solution contains 0.05 mg palonosetron (equivalent to 0.056 mg palonosetron hydrochloride). Each mL also contains 41.5 mg mannitol, 3.0 mg sodium acetate trihydrate, and water for injection (q.s. to 1.0 mL). 

The pH of the solution in the 5 mL and 1.5 mL vials is 4.5 to 5.5. Hydrochloric acid or sodium hydroxide may have been added to adjust pH.
PURPOSE:To obtain the subject food having suppressive activity against absorption of fat from bowels and preventive function against obesity due to excessive intake of fat by compounding a high fat main component with purified gymnema acid derived from acidic precipitate of an extract component obtained from Gymnema sylvestre. CONSTITUTION:Dried leaves of gymnema sylvestre is immersed in hot water of about 60 deg.C for >=5hr and mildly centrifuged with rotation of 1200-1300rpm. The supernatant is dried by lyophillization to obtain powdery extract component. This is dissolved in water. Acidic precipitate is obtained by adjusting the pH of the solution to 3 and purified gymnema acid (i-GA) is obtained from the precipitate. The i-GA is further washed with water and extracted with ethanol and the extract is concentrated under reduced pressure. The concentrated extract is centrifuged after adding acetone and a purified product (p-GA) is precipitated from the supernatant. Thereafter, the objective high fat food having antiobestic function is obtained by compounding a high fat food containing a high fat main component with the purified gymnema acid (p-GA).
The present invention relates to a method for preparing fatigue relieving soybean milk powder with micron xylitol, asiabell, asparagus root, prepared rehmannia root, white fungus, hairy antler and ants powder. Various kinds of traditional soybean milk powder are added with micron codonopsis pilosula, micron radix powder, micron rehmanniae vaporata powder, micron white fungus powder, micron hairy antler powder, micron deer bone powder, micron ant powder and xylitol which are crushed into ultrafine power by high-tech air stream, all kinds of raw material are combined and processed, and the soybean milk powder for relieving fatigue is obtained. The soybean milk powder prepared by the present invention has the obvious efficiency for relieving fatigue and enhancing immunity. Middle-age people and old people can obtain hundreds of kinds of nutrient substances, such as rich proteins, vitamins, minerals, etc. Simultaneously, because the soybean milk is added with the micron hairy antler powder, micron rehmanniae vaporata powder, etc. which are called as jewelries for strengthening yang and nourishing yin in the east, the health care efficiency for strengthening yang, relieving fatigue, nourishing yin and supplementing blood is strengthened. Therefore, the soybean milk powder prepared by the present invention is soybean milk powder health care food which is especially designed for middle-age people and old people all over the world and has the Chinese characteristics. The soybean milk powder has the efficiency for nourishing yin, strengthening yang, nourishing qi and blood, and relieving fatigue.
Smoking is the most important risk factor for chronic obstructive pulmonary disease (COPD), however evidence from large-scale studies on whether secondhand smoke (SHS) increases the risk of COPD is still lacking. We conducted this large longitudinal study to investigate the association between SHS and the development of COPD. This is a longitudinal study. Data on 6519 subjects who were never-smokers, had no history of COPD, and had complete lung function records were extracted from the Taiwan Biobank. They were divided into two groups according to SHS exposure: no exposure and exposure groups. Data were collected when participants enrolled in the study and during regular follow-up. Cox proportional hazards regression models were used to estimate the relative risk (RR) and 95% confidence interval (CI) for the association between SHS and the risk of developing COPD. At 48 months of follow-up, 260 (4%) participants in the no exposure group and 34 (7%) participants in the exposure group developed COPD. The RR of incident COPD development was significantly higher in the exposure group than that in the no exposure group after adjusting for confounders (RR = 1.49; 95% CI 1.04 to 2.14; P value = 0.031). There is a dose-response relationship between the duration of exposure to SHS and the risk of incident COPD, which demonstrates that an additional hour of exposure to SHS per week was associated with a 1.03-fold increased likelihood of developing COPD after adjusting for confounders (RR = 1.03; 95% CI 1.00 to 1.05; P value = 0.027). SHS exposure contributes to the development of COPD. This finding can help raise awareness of the harms of SHS and provide a reference for formulating anti-smoking policies.
Participants will receive one fraction of radiation therapy a day for 5 days each week for 5 weeks along with weekly chemotherapy with Paclitaxel 45 milligram per meter squared (mg/m2) through intravenous (IV)infusion for 1 hour followed by Carboplatin area under the curve (AUC) 2 IV for 30 minutes for approximately 5 or 6 weeks. Once complete, participant will receive Durvalumab, 1500 mg, IV every 4 weeks for 12 months.
This is an open-label immunogenicity and safety study of live attenuated Measles Vaccine (Attenuvax) and Measles-Mumps-Rubella (MMR-II) vaccine administered to healthy children at 6 (n=70), 9 (n=70), or 12 (n=70) months of age. Attenuvax (Measles Virus Vaccine Live, Merck \& Co., Inc) and MMR-II (Measles-Mumps-Rubella Virus Vaccine Live, Merck \& Co., Inc) will be delivered as 0.5 mL per dose, administered subcutaneously. Both vaccines are licensed for use in infants in the United States. MMR-II is recommended as part of the childhood immunization schedule by the AAP and ACIP, and Attenuvax is recommended for use as a single component vaccine in infants 6-11 months particularly for foreign travel and in measles outbreaks79. Infants vaccinated with Attenuvax at 6 or 9 months receive MMR-II at 12 months of age as recommended for follow-up vaccination. Immunization against measles is given as a trivalent formulation with mumps and rubella and is indicated as a primary dose at 12-15 months of age with a second dose recommended routinely at time of school entry, 4-6 years of age, but can be given at any earlier age provided that the interval between the first and second doses is at least 4 weeks .

Two hundred and ten healthy children attending the Palo Alto Medical Clinic will be recruited into one of three cohorts over a five year period. (Table 1). All children in cohort 1 and 2 (6 and 9 month old infants) will receive Attenuvax as part of their participation in this study followed by MMR-II at 12 months of age as part of their routine WCC and not as a study vaccine. Infants recruited into cohort 3, (twelve month old infants) will receive one dose of MMR-II at 12 months. All infants in the study (cohort 1, 2 or 3) are receiving MMR-II at 12 months as part of their routine childhood vaccines. The vaccination schedules is summarized in Table 1. Other immunizations as required for routine WCC will be administered simultaneously. Participation will entail 2-4 visits, 2-3 blood samples, and 1-2 immunizations and will end after the 9-18 month visit, totaling 3 to 12 months time of participation for a subject depending on cohort and if participants opt for a second follow-up blood sample.
INTRODUCTION: High-risk human papillomavirus (HPV) has been detected in distant metastases from cervical cancer (CC) patients, suggesting a role of HPV.
MATERIAL AND METHODS: Here, we included 26 patients with recurrence of CC (2019-2023). With next generation sequencing (NGS) and immunohistochemical staining, primary and recurrent tissues were analyzed for HPV DNA and HPV RNA, p16INK4a expression, and somatic TP53 and RB1 mutations.
RESULTS: All primary and corresponding recurrent tissues were HPV DNA and HPV RNA positive. Within the same tissue, we found complete DNA/RNA agreement in 25/26 (96.2 %) primary and 25/25 (100 %) recurrent tissues, and partial agreement in the remaining sample. There was complete agreement between primary and recurrent tissue in 23/26 (88.5 %) and 23/25 (92.0 %) patients on DNA and RNA, respectively, whereas the remaining showed partial agreement with two genotypes detected in primary and only one of these in recurrent tissue. Except for one sample, all samples from high-risk HPV-positive patients were p16INK4a positive. The low-risk HPV11-positive patient was p16INK4a negative and had a pathogenic TP53 mutation, while the remaining samples were TP53/RB1 mutation negative.
CONCLUSION: In high-risk HPV-positive CC patients, HPV seems to play a role in recurrent disease. Our findings support ongoing research on targeting HPV oncogenes in CC, also in metastatic disease.
Patients undergo eHNS. Depending on post-operative pathology findings, patients may undergo IMRT QD five days a week for 6 weeks, beginning within 6 weeks after surgery. High-risk patients also receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 during radiation therapy.
Participants will meet with a nutritionist to discuss dietary recommendations for patients with prostate cancer undergoing ADT. Participants will self-select a 10-hour window in which to consume all food and beverages (with the exception of black coffee and unsweetened tea in the mornings; water is okay at all times).
FIELD: medicine. SUBSTANCE: method involves inhaling phytoaeroiones as finely divided electrically charged aerosol which electric charge material carrier is aqueous emulsion of essential oils or water decoctions of different alkaloidless plants not belonging to the group of the adaptogens. Essential oils are taken to produce emulsion in proportion of oil to water being equal to 1:1000. Water decoctions are prepared with proportion of raw materials to water being equal to 1:50. Emulsion or decoction are mechanically transformed into finely divided aerosol which is additionally electrically charged in escaping phytoaeroionizer. Biologically active substance concentration in the treatment room air is determined on conversion to essential oil contents as 1-2 mg/m 3  of the room air. Treatment duration is 30-40 min. The number of treatments is 25-30 per medical treatment course to be taken daily. When necessary, phytoaeroionization treatment course is to be repeated in prophylactic purposes 2-3 months later. EFFECT: pronounced increase in adaptation level; lowered morbidity rate; no contraindications. 5 tbl
Determination of the total daily energy expenditure (TDEE) is of great importance as a starting point for professional support and the achievement of physical, aesthetic, and health goals. Considering that TDEE is mainly composed of resting energy expenditure (REE), nutrition and health professionals generally estimate REE and then add values for the thermic effect of food (TFE) and physical activity expenditure. As well as allostatic load and stress may increase the REE, depending on the intensity and duration of the stressor. Based on predictor variables, REE estimating equations are used. However, the values yielded by the estimating equations can be inaccurate due to variations in the characteristics of the population. Considering the lack of validation in the Colombian population to estimate the REE, the objective of the present research study is to compare the methods for estimating resting energy expenditure in the Colombian population with different levels of physical activity. This is a cross-sectional-observational study that will be carried out by means of the guidelines for strengthening the reporting of observational studies in nutritional epidemiology (STROBE-Nut). Likewise, the data collection will be carried out with a pilot test where ISAK-certified personnel in levels 2 and 3 will offer specialized training to the research assistants to allow standardization in the taking of anthropometric measurements, which minimizes the error in the data collection. This process prior to data collection allows adjustment of the methodology and procedures during the research. In addition, technical staff with a master's degree in sports science, a master's degree in exercise physiology, or a medical degree will be available for the measurement of the REE by indirect calorimetry. The measurement will be performed after device calibration and a pilot test will be performed to standardize the work methodology and calculate the coefficient of variation of the equipment.

The NRG project is developed by the Research Division of the Dynamical Business \& Science Society-DBSS International with the support of University CES, University of Cordoba, the R\&D department of ARTHROS IPS, Smart Fit, INDEPORTES Antioquia, and the University Santo Tomás in Bogotá. The development of the equation to estimate the REE will be carried out with multiple regression models under traditional and Bayesian approaches with three independent variables. It is expected to obtain a simple and valid equation to estimate the REE and contribute to the good practices of Colombian practitioners in health sciences, exercise, and sports.
BACKGROUND: The hiatal ligament, as the anatomical landmark for the completion of total mesorectal excision (TME) for ultra-low rectal cancer, represents a continuation of the longitudinal muscle of the rectum. It receives vascular supply from the median sacral artery and contains lymphatic vessels. In cases where ultra-low rectal cancer is located in the posterior rectal wall, the hiatal ligament may theoretically serve as an anatomical region susceptible to direct tumor cell spread or distant metastasis.
OBJECTIVE: To evaluate the effect of circumferential tumor location (CTL) on postoperative survival of low rectal cancer and to determine the effect of total hiatal ligament excision (THLE) on the prognosis of patients with posterior rectal cancer.
METHODS: Patients with ultra-low rectal cancer who underwent laparoscopic surgery between March 2014 and October 2021 were enrolled in this study. Propensity score matching (PSM) analysis was used to compare the clinicopathological characteristics and prognosis of patients in the posterior group and the non-posterior group. Prognostic factors were identified using COX regression. PSM analysis was also used in the posterior tumor subgroup to compare the clinicopathological characteristics and prognosis of patients in the hiatal ligament traditional transection (HLTT) and THLE groups.
RESULTS: After PSM, OS, and DFS were comparable between the posterior and non-posterior groups. Similarly, no difference was noted in the local recurrence rate between the two groups (p = 0.23). The prognosis of ultra-low rectal cancer was not affected by CTL. However, the local recurrence rate was significantly lower in the THLE group compared with the HLTT group (p = 0.023). Multivariate analysis of the posterior group identified CRM, TNM stage III, and HLTT as independent risk factors for local recurrence-free survival.
CONCLUSIONS: CTL is not a prognostic risk factor for low rectal cancer. In posterior wall tumors, THLE significantly reduces the local recurrence rate for low rectal cancer.
The invention relates to the preparation and utilities of immunnomodulatory peptide. The effect of Dermatophagoides farinae fragments (Der f 2 N-peptides) which do not bind specific IgE in conjunction with fungal immunomodulatory protein (FIP-fve) on Treg-cells derived from allergic rhinitis individuals was evaluated. The percentage of Foxp3+ Treg-cells in CD4+CD25+ T cells was significantly increased in D. farinae-allergic patients by Der f 2 N-peptides in conjunction with FIP-fve. Both IL-10+ and TGF- β + Treg-cells were significantly increased in the presence of Der f 2 N-peptides and FIP-fve in comparison with medium control. The percentage of IL-10+ and TGF- β + cells in CD4+CD25+Foxp3+ Treg cells can be upregulated by Der f 2 N-peptides in conjunction with FIP-fve only in D. farinae allergic individuals. These results indicate that the invention has therapeutic effects on augmentation of Treg-cells derived from allergic individuals.